Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Director departure
Appointed director
|
|
VOLITIONRX LTD (VNRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Quarterly results |
| 06/30/2023 |
8-K
| Appointed a new director |
| 05/10/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/25/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/16/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 08/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...|
Docs:
|
"Underwriting Agreement, by and between VolitionRx Limited and Newbridge Securities Corporation",
"Opinion of Stradling, Yocca, Carlson & Rauth, P.ßC",
"VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock HENDERSON, Nevada, July 28, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Volition. In addition, Volition intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual siz...",
"HENDERSON, Nevada, July 29, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million. In addition, Volition has granted the underwriter in the offering a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the offering. The offering is expected to close on or about August 2, 2022, subject to ...",
"HENDERSON, Nevada, August 2, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, including the exercise in full of the underwriter’s overallotment option, at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering were $6.9 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corp..." |
|
| 06/14/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/30/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/29/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 11/10/2021 |
8-K
| Quarterly results |
| 08/11/2021 |
8-K
| Quarterly results |
| 06/22/2021 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K
| Quarterly results |
| 03/29/2021 |
8-K
| Quarterly results |
| 03/22/2021 |
8-K
| Quarterly results |
| 02/12/2021 |
8-K
| Quarterly results |
| 02/09/2021 |
8-K
| Quarterly results |
| 02/02/2021 |
8-K
| Quarterly results |
| 01/15/2021 |
8-K
| Quarterly results |
| 12/03/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors AUSTIN, Texas, December 3, 2020 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Dr. Tom Butera DVM, to the Company’s Board of Directors, effective December 1, 2020. Dr. Butera was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees. “We are pleased to welcome Tom to the Volition Board of Directors,” said Martin Faulkes, the Company’s Chairman of the Board. “Tom is a proven entrepreneur, innovator and value-based leader in the healthcare field, and we are confident he will bring a d..." |
|
| 11/12/2020 |
8-K
| Quarterly results |
| 08/13/2020 |
8-K
| Quarterly results |
| 06/22/2020 |
8-K
| Quarterly results |
| 05/22/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, between the Company and National Securities Corporation, as representative of the several Underwriters named therein",
"Opinion of Stradling Yocca Carlson & Rauth, P.C",
"VolitionRx Announces Proposed Underwritten Public Offering of Common Stock AUSTIN, Texas, May 19, 2020 PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any. All shares of common stock in the offering are being offered by Volition. The proposed offering is subject to market and other conditions, and there can be no assura...",
"VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock AUSTIN, Texas, May 20, 2020 PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the pricing of its previously announced underwritten public offering. Volition is offering 4,365,000 shares of common stock, par value $0.001 per share, at a price to the public of $2.75 per share. In connection with the offering, Volition has also granted the underwriters a 30-day option to purchase up to an additional 654,750 shares of its common stock offered in the public offering, at the same public offering price p...",
"VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock AUSTIN, Texas, May 22, 2020 PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the closing of its previously announced underwritten public offering of an aggregate of 5,019,750 shares of common stock, including the exercise in full of the overallotment option, at a public offering price of $2.75 per share for total gross proceeds of $13.8 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Volition. All of the shares of common stock sold in the ..." |
|
| 05/07/2020 |
8-K
| Quarterly results |
| 04/23/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 02/20/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 10/09/2019 |
8-K
| Quarterly results |
|
|
|